American College of Cardiology

Blomström-Lundqvist ET AL., MANAGEMENT OF PATIENTS WITH Supraventricular Arrhythmias
J Am Coll Cardiol 2003;42:1493–531

ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias

A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias)

References
1. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guide- lines for the management of patients with atrial fibrillation: exec- utive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation 2001;104: 2118-50.
2. Campbell RW. Supraventricular tachycardia: occasional nuisance or frequent threat? Eur Heart J 1996;17 Suppl C:21-5.
3. Baine WB, Yu W, Weis KA. Trends and outcomes in the hospital- ization of older Americans for cardiac conduction disorders or arrhythmias, 1991-1998. J Am Geriatr Soc 2001;49:763-70.
4. Cairns CB, Niemann JT. Intravenous adenosine in the emergency department management of paroxysmal supraventricular tachy- cardia. Ann Emerg Med 1991;20:717-21.
5. Connors S, Dorian P. Management of supraventricular tachycardia in the emergency department. Can J Cardiol 1997;13Suppl A: 19A-24A.
6. Luderitz B, Manz M. Pharmacologic treatment of supraventricu- lar tachycardia: the German experience. Am J Cardiol 1992;70: 66A-73A.
7. Getchell WS, Larsen GC, Morris CD, McAnulty JH. Epidemiology of syncope in hospitalized patients. J Gen Intern Med 1999;14:677-87.
8. Camm AJ, Obel OA. Epidemiology and mechanism of atrial fib- rillation and atrial flutter. Am J Cardiol 1996;78:3-11.
9. U.S. Department of Health & Human Services (DHHS): Centers for Disease Control Vital and Health Statistics. Current estimates from the National Health Interview Survey (1996). Publication No. (PHS) 99-1528. 1999.
10. Orejarena LA, Vidaillet H Jr, DeStefano F, et al. Paroxysmal supraventricular tachycardia in the general population. J Am Coll Cardiol 1998;31:150-7.
11. Pizzetti F, Turazza FM, Franzosi MG, et al. Incidence and prog- nostic significance of atrial fibrillation in acute myocardial infarc- tion: the GISSI-3 data. Heart 2001;86:527-32.
12. Frost L, Molgaard H, Christiansen EH, Hjortholm K, Paulsen PK, Thomsen PE. Atrial fibrillation and flutter after coronary artery bypass surgery: epidemiology, risk factors and preventive trials. Int J Cardiol 1992;36:253-61.
13. Mathew J, Hunsberger S, Fleg J, Mc SF, Williford W, Yusuf S. Incidence, predictive factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure. Chest 2000;118:914-22.
14. Goyal R, Zivin A, Souza J, et al. Comparison of the ages of tachy- cardia onset in patients with atrioventricular nodal reentrant tachycardia and accessory pathway-mediated tachycardia. Am Heart J 1996;132:765-7.
15. Rodriguez LM, de Chillou C, Schlapfer J, et al. Age at onset and gender of patients with different types of supraventricular tachy- cardias. Am J Cardiol 1992;70:1213-5.
16. Agency for Healthcare Policy Research (AHCPR), Center for Organization and Delivery Studies. Healthcare Cost and Utilization Project (HCUP-3) multilevel clinical classification software (CCS) categories 7.2.9.1, 3, 4, and 7. 1996.
17. U.S. Department of Health & Human Services (DHHS): Centers for Disease Control Vital and Health Statistics. National hospital discharge survey: annual summary with detailed diagnosis and procedure data (1999). DHHS Publication No. (PHS) 2001-1722. 2001.
18. Granada J, Uribe W, Chyou PH, et al. Incidence and predictors of atrial flutter in the general population. J Am Coll Cardiol 2000; 36:2242-6.
19. Alpert J, Braunwald E. Pathological and clinical manifestations of acute myocardial infarction. In: Heart disease: a textbook of car- diovascular medicine. 1980 ed. Philadelphia, PA: WB Saunders Company, 1980:1309-52.
20. Josephson ME. Clinical cardiac electrophysiology–techniques and interpretation. 2nd ed. Philadelphia, PA: Lea and Febiger, 1992:117.
21. Spach MS, Dolber PC, Heidlage JF. Interaction of inhomo- geneities of repolarization with anisotropic propagation in dog atria: a mechanism for both preventing and initiating reentry. Circ Res 1989;65:1612-31.
22. James TN. The sinus node. Am J Cardiol 1977;40:965-86.
23. Masson-Pevet M, Bleeker WK, Gros D. The plasma membrane of leading pacemaker cells in the rabbit sinus node. A qualitative and quantitative ultrastructural analysis. Circ Res 1979;45:621-9.
24. Bleeker WK, Mackaay AJ, Masson-Pevet M, Bouman LN, Becker AE. Functional and morphological organization of the rabbit sinus node. Circ Res 1980;46:11-22.
25. Boineau JP, Schuessler RB, Hackel DB, Miller CB, Brockus CW, Wylds AC. Widespread distribution and rate differentiation of the atrial pacemaker complex. Am J Physiol 1980;239:H406-15.
26. Kodama I, Boyett MR. Regional differences in the electrical activity of the rabbit sinus node. Pflugers Arch 1985;404:214-26. 27. Kwong KF, Schuessler RB, Green KG, et al. Differential expres- sion of gap junction proteins in the canine sinus node. Circ Res 1998;82:604-12.
28. Wu J, Schuessler RB, Rodefeld MD, Saffitz JE, Boineau JP. Morphological and membrane characteristics of spider and spin- dle cells isolated from rabbit sinus node. Am J Physiol Heart Circ Physiol 2001;280:H1232-40.
29. Boyett MR, Honjo H, Yamamoto M, Nikmaram MR, Niwa R, Kodama I. Downward gradient in action potential duration along conduction path in and around the sinoatrial node. Am J Physiol 1999;276:H686-98.
30. Coppen SR, Kodama I, Boyett MR, et al. Connexin45, a major connexin of the rabbit sinoatrial node, is co-expressed with con- nexin43 in a restricted zone at the nodal-crista terminalis border. J Histochem Cytochem 1999;47:907-18.
31. Hogan PM, Davis LD. Evidence for specialized fibers in the canine right atrium. Circ Res 1968;23:387-96.
32. Spach MS, Dolber PC, Anderson PA. Multiple regional differ- ences in cellular properties that regulate repolarization and con- traction in the right atrium of adult and newborn dogs. Circ Res 1989;65:1594-611.
33. Feng J, Yue L, Wang Z, Nattel S. Ionic mechanisms of regional action potential heterogeneity in the canine right atrium. Circ Res 1998;83:541-51.
34. Li D, Zhang L, Kneller J, Nattel S. Potential ionic mechanism for repolarization differences between canine right and left atrium. Circ Res 2001;88:1168-75.
35. Munk AA, Adjemian RA, Zhao J, Ogbaghebriel A, Shrier A. Electrophysiological properties of morphologically distinct cells isolated from the rabbit atrioventricular node. J Physiol 1996;493 (Pt 3):801-18.
36. Zipes DP, Knope RF. Electrical properties of the thoracic veins. Am J Cardiol 1972;29:372-6.
37. Cheung DW. Electrical activity of the pulmonary vein and its interaction with the right atrium in the guinea-pig. J Physiol 1981;314:445-56.
38. Cheung DW. Pulmonary vein as an ectopic focus in digitalis- induced arrhythmia. Nature 1981;294:582-4.
39. Tavi P, Laine M, Weckstrom M. Effect of gadolinium on stretch- induced changes in contraction and intracellularly recorded action- and afterpotentials of rat isolated atrium. Br J Pharmacol 1996;118:407-13.
40. Levi R, Malm JR, Bowman FO, Rosen MR. The arrhythmogenic actions of histamine on human atrial fibers. Circ Res 1981;49:545-50.
41. Henning B, Wit AL. The time course of action potential repolar- ization affects delayed afterdepolarization amplitude in atrial fibers of the canine coronary sinus. Circ Res 1984;55:110-5.
42. Rozanski GJ, Lipsius SL. Electrophysiology of functional sub- sidiary pacemakers in canine right atrium. Am J Physiol 1985;249:H594-H603.
43. Tseng GN, Wit AL. Characteristics of a transient inward current that causes delayed afterdepolarizations in atrial cells of the canine coronary sinus. J Mol Cell Cardiol 1987;19:1105-19.
44. Luk HN, Lin CI, Wei J, Chang CL. Depressant effects of isoflu- rane and halothane on isolated human atrial fibers. Anesthesiology 1988;69:667-76.
45. Hou ZY, Lin CI, Chiu TH, Chiang BN, Cheng KK, Ho LT. Somatostatin effects in isolated human atrial fibres. J Mol Cell Cardiol 1987;19:177-85.
46. Johnson N, Danilo P Jr, Wit AL, Rosen MR. Characteristics of initiation and termination of catecholamine-induced triggered activity in atrial fibers of the coronary sinus. Circulation 1986;74:1168-79.
47. Wang YG, Huser J, Blatter LA, Lipsius SL. Withdrawal of acetyl- choline elicits Ca2+-induced delayed afterdepolarizations in cat atrial myocytes. Circulation 1997;96:1275-81.
48. Scher DL, Arsura EL. Multifocal atrial tachycardia: mechanisms, clinical correlates, and treatment. Am Heart J 1989;118:574-80.
49. McCord J, Borzak S. Multifocal atrial tachycardia. Chest 1998;113:203-9.
50. Kirchhof P, Eckardt L, Monnig G, et al. A patient with “atrial tor- sades de pointes”. J Cardiovasc Electrophysiol 2000;11:806-11.
51. Chen YJ, Chen SA, Chang MS, Lin CI. Arrhythmogenic activity of cardiac muscle in pulmonary veins of the dog: implication for the genesis of atrial fibrillation. Cardiovasc Res 2000;48:265-73.
52. Feld GK, Venkatesh N, Singh BN. Pharmacologic conversion and suppression of experimental canine atrial flutter: differing effects of d-sotalol, quinidine, and lidocaine and significance of changes in refractoriness and conduction. Circulation 1986;74:197-204.
53. Feld GK, Venkatesh N, Singh BN. Effects of N-acetylpro- cainamide and recainam in the pharmacologic conversion and suppression of experimental canine atrial flutter: significance of changes in refractoriness and conduction. J Cardiovasc Pharmacol 1988;11:573-80.
54. Allessie MA, Bonke FI, Schopman FJ. Circus movement in rab- bit atrial muscle as a mechanism of tachycardia. Circ Res 1973;33:54-62.
55. Wood KA, Drew BJ, Scheinman MM. Frequency of disabling symptoms in supraventricular tachycardia. Am J Cardiol 1997;79:145-9.
56. Luchsinger JA, Steinberg JS. Resolution of cardiomyopathy after ablation of atrial flutter. J Am Coll Cardiol 1998;32:205-10. 57. Chiladakis JA, Vassilikos VP, Maounis TN, Cokkinos DV, Manolis AS. Successful radiofrequency catheter ablation of auto- matic atrial tachycardia with regression of the cardiomyopathy picture. Pacing Clin Electrophysiol 1997;20:953-9.
58. Wu EB, Chia HM, Gill JS. Reversible cardiomyopathy after radiofrequency ablation of lateral free-wall pathway-mediated incessant supraventricular tachycardia. Pacing Clin Electro- physiol 2000;23:1308-10.
59. Kessler DK, Kessler KM, Myerburg RJ. Ambulatory electrocar- diography: a cost per management decision analysis. Arch Intern Med 1995;155:165-9.
60. Lantz DA. Efficacy of Holter monitors. Ann Intern Med 1996;125: 697-8.
61. Crawford MH, Bernstein SJ, Deedwania PC, et al. ACC/AHA guidelines for ambulatory electrocardiography: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to revise the guidelines for ambulatory electrocardiography). Circulation 1999;100:886-93.
62. Fogel RI, Evans JJ, Prystowsky EN. Utility and cost of event recorders in the diagnosis of palpitations, presyncope, and syn- cope. Am J Cardiol 1997;79:207-8
63. Seidl K, Rameken M, Breunung S, et al. Diagnostic assessment of recurrent unexplained syncope with a new subcutaneously implantable loop recorder. Reveal-Investigators. Europace 2000;2:256-62.
64. Tritto M, Dicandia CD, Calabrese P. Overdrive atrial stimulation during transesophageal electrophysiological study: usefulness of post-pacing VA interval analysis in differentiating supraventricu- lar tachycardias with 1:1 atrio-ventricular relationship. Int J Cardiol 1997;62:37-45.
65. Volkmann H, Kuhnert H, Dannberg G. Electrophysiological eval- uation of tachycardias using transesophageal pacing and record- ing. Pacing Clin Electrophysiol 1990;13:2044-7.
66. Kay GN, Pressley JC, Packer DL, Pritchett EL, German LD, Gilbert MR. Value of the 12-lead electrocardiogram in discrimi- nating atrioventricular nodal reciprocating tachycardia from cir- cus movement atrioventricular tachycardia utilizing a retrograde accessory pathway. Am J Cardiol 1987;59:296-300.
67. Josephson ME. Paroxysmal supraventricular tachycardia: an elec- trophysiologic approach. Am J Cardiol 1978;41:1123-6.
68. Lee KL, Chun HM, Liem LB, Sung RJ. Effect of adenosine and verapamil in catecholamine-induced accelerated atrioventricular junctional rhythm: insights into the underlying mechanism. Pacing Clin Electrophysiol 1999;22:866-70.
69. Glatter KA, Cheng J, Dorostkar P, et al. Electrophysiologic effects of adenosine in patients with supraventricular tachycardia. Circulation 1999;99:1034-40.
70. Overholt ED, Rheuban KS, Gutgesell HP, Lerman BB, DiMarco JP. Usefulness of adenosine for arrhythmias in infants and chil- dren. Am J Cardiol 1988;61:336-40.
71. Dancy M, Camm AJ, Ward D. Misdiagnosis of chronic recurrent ventricular tachycardia. Lancet 1985;2:320-3.
72. Stewart RB, Bardy GH, Greene HL. Wide complex tachycardia: misdiagnosis and outcome after emergent therapy. Ann Intern Med 1986;104:766-71.
73. Buxton AE, Marchlinski FE, Doherty JU, Flores B, Josephson ME. Hazards of intravenous verapamil for sustained ventricular tachycardia. Am J Cardiol 1987;59:1107-10.
74. Wellens HJ, Bar FW, Lie KI. The value of the electrocardiogram in the differential diagnosis of a tachycardia with a widened QRS complex. Am J Med 1978;64:27-33.
75. Harvey WP, Ronan JA Jr. Bedside diagnosis of arrhythmias. Prog Cardiovasc Dis 1966;8:419-45.
76. Sager PT, Bhandari AK. Wide complex tachycardias: differential diagnosis and management. Cardiol Clin 1991;9:595-618. 77. Marriott HJ. Differential diagnosis of supraventricular and ventricular tachycardia. Geriatrics 1970;25:91-101.
78. Brugada P, Brugada J, Mont L, Smeets J, Andries EW. A new approach to the differential diagnosis of a regular tachycardia with a wide QRS complex. Circulation 1991;83:1649-59.
79. Wellens HJ. Electrophysiology: ventricular tachycardia: diagno- sis of broad QRS complex tachycardia. Heart 2001;86:579-85.
80. Coumel P, Leclercq JF, Attuel P, Maisonblanche P. The QRS morphology in post-myocardial infarction ventricular tachycardia: a study of 100 tracings compared with 70 cases of idiopathic ventricular tachycardia. Eur Heart J 1984;5:792-805.
81. Morady F, Baerman JM, DiCarlo LA Jr, DeBuitleir M, Krol RB, Wahr DW. A prevalent misconception regarding wide-complex tachycardias. JAMA 1985;254:2790-2.
82. Tchou P, Young P, Mahmud R, Denker S, Jazayeri M, Akhtar M. Useful clinical criteria for the diagnosis of ventricular tachycardia. Am J Med 1988;84:53-6.
83. Mehta D, Wafa S, Ward DE, Camm AJ. Relative efficacy of various physical manoeuvres in the termination of junctional tachy- cardia. Lancet 1988;1:1181-5.
84. Gorgels AP, van den DA, Hofs A, et al. Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia. Am J Cardiol 1996;78:43-6.
85. Ho DS, Zecchin RP, Richards DA, Uther JB, Ross DL. Double- blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. Lancet 1994;344:18-23.
86. Scheinman MM, Levine JH, Cannom DS, et al, on behalf of the Intravenous Amiodarone Multicenter Investigators Group. Dose- ranging study of intravenous amiodarone in patients with life- threatening ventricular tachyarrhythmias. Circulation 1995;92: 3264-72.
87. Levine JH, Massumi A, Scheinman MM, et al. Intravenous amio- darone for recurrent sustained hypotensive ventricular tach- yarrhythmias. Intravenous Amiodarone Multicenter Trial Group. J Am Coll Cardiol 1996;27:67-75.
88. Advanced Cardiovascular Life Support: Introduction to ACLS 2000: Overview of Recommended Changes in ACLS From the Guidelines 2000 Conference. [abstr]. Circulation 2000;102:I86-9.
89. Zipes DP, DiMarco JP, Gillette PC, et al. Guidelines for clinical intracardiac electrophysiological and catheter ablation proce- dures: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Intracardiac Electrophysiologic and Catheter Ablation Procedures), developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 1995;26:555-73.
90. Rankin AC, Brooks R, Ruskin JN, McGovern BA. Adenosine and the treatment of supraventricular tachycardia. Am J Med 1992;92:655-64.
91. Waxman HL, Myerburg RJ, Appel R, Sung RJ. Verapamil for control of ventricular rate in paroxysmal supraventricular tachy- cardia and atrial fibrillation or flutter: a double-blind randomized cross-over study. Ann Intern Med 1981;94:1-6.
92. Amsterdam EA, Kulcyski J, Ridgeway MG. Efficacy of cardioselective beta-adrenergic blockade with intravenously administered metoprolol in the treatment of supraventricular tachyarrhythmias. J Clin Pharmacol 1991;31:714-8.
93. Das G, Tschida V, Gray R, et al. Efficacy of esmolol in the treat- ment and transfer of patients with supraventricular tachyarrhyth- mias to alternate oral antiarrhythmic agents. J Clin Pharmacol 1988;31:714-8.
94. Holt P, Crick JC, Davies DW, Curry P. Intravenous amiodarone in the acute termination of supraventricular arrhythmias. Int J Cardiol 1985;8:67-79.
95. Hohnloser SH, Zabel M. Short- and long-term efficacy and safe- ty of flecainide acetate for supraventricular arrhythmias. Am J Cardiol 1992;70:3A-9A.
96. Glatter KA, Dorostkar PC, Yang Y, et al. Electrophysiological effects of ibutilide in patients with accessory pathways. Circulation 2001;104:1933-9.
97. Manz M, Mletzko R, Jung W, Luderitz B. Electrophysiological and haemodynamic effects of lidocaine and ajmaline in the man- agement of sustained ventricular tachycardia. Eur Heart J 1992;13:1123-8.
98. Part 1: Introduction to the International Guidelines 2000 for CPR and ECC: a consensus on science. Circulation 2000;102:I1-11.
99. Sharma AD, Klein GJ, Yee R. Intravenous adenosine triphosphate during wide QRS complex tachycardia: safety, therapeutic efficacy, and diagnostic utility. Am J Med 1990;88:337-43.
100. Ghuran A, Nolan J. Recreational drug misuse: issues for the car- diologist. Heart 2000;83:627-33.
101. Steinherz L, Yalahom J. Cardiac toxicity. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer, principles and practice of oncolo- gy. Philadelphia, PA: Lippincott, Williams & Wilkins; 2001:2904- 21.
102. Singal PK, Deally CM, Weinberg LE. Subcellular effects of adri- amycin in the heart: a concise review. J Mol Cell Cardiol 1987;19:817-28.
103. Sinha BK, Katki AG, Batist G, Cowan KH, Myers CE. Adriamycin-stimulated hydroxyl radical formation in human breast tumor cells. Biochem Pharmacol 1987;36:793-6.
104. Boineau JP, Canavan TE, Schuessler RB, Cain ME, Corr PB, Cox JL. Demonstration of a widely distributed atrial pacemaker com- plex in the human heart. Circulation 1988;77:1221-37.
105. Olgin J, Zipes D. Specific arrhythmias: diagnosis and treatment. In: Braunwald E, Zipes D, Libby P, eds. Heart disease: a textbook of cardiovascular medicine. 6th ed. Philadelphia, PA: Saunders; 2001:815-89.
106. Chierichetti SM, Moise G, Galeone M, Fiorella G, Lazzari R. Beta-blockers and psychic stress: a double-blind, placebo-con- trolled study of bopindolol vs lorazepam and butalbital in surgical patients. Int J Clin Pharmacol Ther Toxicol 1985;23:510-4.
107. Fogari R, Zoppi A, Corradi L, et al. Comparison of bisoprolol and diazepam in the treatment of cardiac neurosis. Cardiovasc Drugs Ther 1992;6:249-53.
108. Scharbach H. [A double blind trial: oxprenolol/diazepam (author's transl)]. Encephale 1981;7:51-8.
109. Schweizer R, Roth WT, Elbert T. Effect of two beta-blockers on stress during mental arithmetic. Psychopharmacology (Berl) 1991;105:573-7.
110. van Vliet IM, den Boer JA, Westenberg HG. Psycho- pharmacological treatment of social phobia; a double blind place- bo controlled study with fluvoxamine. Psychopharmacology (Berl) 1994;115:128-34.
111. van der Linden GJ, Stein DJ, van Balkom AJ. The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 2000;15 Suppl 2:S15-S23.
112. Stein DJ, Stein MB, Goodwin W, Kumar R, Hunter B. The selec- tive serotonin reuptake inhibitor paroxetine is effective in more generalized and in less generalized social anxiety disorder. Psychopharmacology (Berl) 2001;158:267-72.
113. Asnis GM, Hameedi FA, Goddard AW, et al. Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo- controlled study in outpatients. Psychiatry Res 2001;103:1-14.
114. Gruppo Italiano per lo Studio della Streptochi-nasi nell’Infarto Miocardio (GISSI). Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet 1987;2:871-4.
115. Schomig A, Kastrati A, Dirschinger J, et al, for the Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. Coronary stent- ing plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. N Engl J Med 2000;343:385-91.
116. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet 1981;2:823-7.
117. First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986;2:57- 66.
118. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997;349:375-80.
119. The Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. 3-year follow-up of patients randomised in the metoprolol in dilated cardiomyopathy trial. Lancet 1998;351:1180-1.
120. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a ran- domised trial. Lancet 1999;353:9-13.
121. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001;344:501-9.
122. Mintz G, Pizzarello R, Klein I. Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment. J Clin Endocrinol Metab 1991;73:146-50.
123. Milner MR, Gelman KM, Phillips RA, Fuster V, Davies TF, Goldman ME. Double-blind crossover trial of diltiazem versus propranolol in the management of thyrotoxic symptoms. Pharmacotherapy 1990;10:100-6.
124. DaCosta J. An irritable heart. Am J Med Sci 1871;27:145-63.
125. Morillo CA, Klein GJ, Thakur RK, Li H, Zardini M, Yee R. Mechanism of ‘inappropriate’ sinus tachycardia: role of sympa- thovagal balance. Circulation 1994;90:873-7.
126. Bauernfeind RA, Amat YL, Dhingra RC, Kehoe R, Wyndham C, Rosen KM. Chronic nonparoxysmal sinus tachycardia in other- wise healthy persons. Ann Intern Med 1979;91:702-10.
127. Sgarbossa EB, Yamanouchi Y, Rejna T, et al. Autonomic imbal- ance in patients with inappropriate sinus tachycardia. J Am Coll Cardiol 1995;193A.s
128. Cossu SF, Steinberg JS. Supraventricular tachyarrhythmias involving the sinus node: clinical and electrophysiologic charac- teristics. Prog Cardiovasc Dis 1998;41:51-63.
129. Krahn AD, Yee R, Klein GJ, Morillo C. Inappropriate sinus tachy- cardia: evaluation and therapy. J Cardiovasc Electrophysiol 1995;6:1124-8.
130. Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick AP, Scheinman MM. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol 1997;29:709-15.
131. Foster MC, Levine PA. Use of verapamil to control an inappro- priate chronic sinus tachycardia. Chest 1984;85:697-9.
132. Ragueneau I, Laveille C, Jochemsen R, Resplandy G, Funck- Brentano C, Jaillon P. Pharmacokinetic-pharmacodynamic mod- eling of the effects of ivabradine, a direct sinus node inhibitor, on ?heart rate in healthy volunteers. Clin Pharmacol Ther 1998;64:192-203.
133. Lee RJ, Kalman JM, Fitzpatrick AP, et al. Radiofrequency catheter modification of the sinus node for “inappropriate” sinus tachycardia. Circulation 1995;92:2919-28.
134. Yee R, Guiraudon GM, Gardner MJ, Gulamhusein SS, Klein GJ. Refractory paroxysmal sinus tachycardia: management by subto- tal right atrial exclusion. J Am Coll Cardiol 1984;3:400-4.
135. Esmailzadeh B, Bernat R, Winkler K, Meybehm M, Pfeiffer D, Kirchhoff PG. Surgical excision of the sinus node in a patient with inappropriate sinus tachycardia. J Thorac Cardiovasc Surg 1997;114:861-4.
136. Waspe LE, Chien WW, Merillat JC, Stark SI. Sinus node modifi- cation using radiofrequency current in a patient with persistent inappropriate sinus tachycardia. Pacing Clin Electrophysiol 1994;17:1569-76.
137. Sato T, Mitamura H, Murata M, et al. Electrophysiologic findings of a patient with inappropriate sinus tachycardia cured by selec- tive radiofrequency catheter ablation. J Electrocardiol 2000;33:381-6.
138. Mischke K, Stellbrink C, Hanrath P. Evidence of sinoatrial block as a curative mechanism in radiofrequency current ablation of inappropriate sinus tachycardia. J Cardiovasc Electrophysiol 2001;12:264-7.
139. de Paola AA, Horowitz LN, Vattimo AC, et al. Sinus node artery occlusion for treatment of chronic nonparoxysmal sinus tachycar- dia. Am J Cardiol 1992;70:128-30.
140. Man KC, Knight B, Tse HF, et al. Radiofrequency catheter abla- tion of inappropriate sinus tachycardia guided by activation map- ping. J Am Coll Cardiol 2000;35:451-7.
141. Jayaprakash S, Sparks PB, Vohra J. Inappropriate sinus tachycardia (IST): management by radiofrequency modification of sinus node. Aust N Z J Med 1997;27:391-7.
142. Shen WK, Low PA, Jahangir, A et al. Is sinus node modification appropriate for inappropriate sinus tachycardia with features of postural orthostatic tachycardia syndrome Pacing Clin Electrophysiol 2001;24:217-30.
143. MacLean A, Allen E, Magath T. Orthostatic tachycardia and orthostatic hypotension: defects in the return of venous blood to the heart. Am Heart J 1944;27:145-63.
144. Rosen SG, Cryer PE. Postural tachycardia syndrome. Reversal of sympathetic hyperresponsiveness and clinical improvement during sodium loading. Am J Med 1982;72:847-50.
145. Schondorf R, Low PA. Idiopathic postural orthostatic tachycardia syndrome: an attenuated form of acute pandysautonomia? Neurology 1993;43:132-7.
146. Fouad FM, Tadena-Thome L, Bravo EL, Tarazi RC. Idiopathic hypovolemia. Ann Intern Med 1986;104:298-303.
147. Streeten DH. Orthostatic intolerance: a historical introduction to the pathophysiological mechanisms. Am J Med Sci 1999;317:78- 87.
148. Hoeldtke RD, Davis KM, Joseph J, Gonzales R, Panidis IP, Friedman AC. Hemodynamic effects of octreotide in patients with autonomic neuropathy. Circulation 1991;84:168-76.
149. Tani H, Singer W, McPhee BR, et al. Splanchnic-mesenteric capacitance bed in the postural tachycardia syndrome (POTS). Auton Neurosci 2000;86:107-13.
150. Hoeldtke RD, Streeten DH. Treatment of orthostatic hypotension with erythropoietin. N Engl J Med 1993;329:611-5.
151. Khurana RK. Orthostatic intolerance and orthostatic tachycardia: a heterogeneous disorder. Clin Auton Res 1995;5:12-8.
152. Grubb BP, Kanjwal MY, Kosinski DJ. Review: the postural orthostatic tachycardia syndrome: current concepts in pathophysiology diagnosis and management. J Interv Card Electrophysiol 2001;5:9-16.
153. Farquhar WB, Taylor JA, Darling SE, Chase KP, Freeman R. Abnormal baroreflex responses in patients with idiopathic ortho- static intolerance. Circulation 2000;102:3086-91.
154. Shannon JR, Flattem NL, Jordan J, et al. Orthostatic intolerance and tachycardia associated with norepinephrine- transporter deficiency. N Engl J Med 2000;342:541-9.
155. Stewart JM, Weldon A. The relation between lower limb pooling and blood flow during orthostasis in the postural orthostatic tachycardia syndrome of adolescents. J Pediatr 2001;138:512-9.
156. Jacob G, Costa F, Shannon JR, et al. The neuropathic postural tachycardia syndrome. N Engl J Med 2000;343:1008-14.
157. Stewart JM. Pooling in chronic orthostatic intolerance: arterial vasoconstrictive but not venous compliance defects. Circulation 2002;105:2274-81.
158. Stewart JM, Weldon A. Reflex vascular defects in the orthostatic tachycardia syndrome of adolescents. J Appl Physiol 2001;90:2025-32.
159. Vernino S, Low PA, Fealey RD, Stewart JD, Farrugia G, Lennon VA. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med 2000;343:847-55.
160. Singer W, Shen WK, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Low PA. Evidence of an intrinsic sinus node abnormality in patients with postural tachycardia syndrome. Mayo Clin Proc 2002;77:246-52.
161. Sandroni P, Opfer-Gehrking TL, McPhee BR, Low PA. Postural tachycardia syndrome: clinical features and follow-up study. Mayo Clin Proc 1999;74:1106-10.
162. De Lorenzo F, Hargreaves J, Kakkar VV. Possible relationship between chronic fatigue and postural tachycardia syndromes. Clin Auton Res 1996;6:263-4.
163. Bou-Holaigah I, Rowe PC, Kan J, Calkins H. The relationship between neurally mediated hypotension and the chronic fatigue syndrome. JAMA 1995;274:961-7.
164. Stewart JM, Gewitz MH, Weldon A, Arlievsky N, Li K, Munoz J. Orthostatic intolerance in adolescent chronic fatigue syndrome. Pediatrics 1999;103:116-21.
165. Low P, Schondorf R, Novak V, et al. Postural tachycardia syn- dromes. In: Low PA, ed. Clinical autonomic disorders: evaluation and management. 2nd ed. Philadelphia, PA: Lippincott-Raven; 1997:681-97.
166. Ten Harkel AD, Van Lieshout JJ, Wieling W. Treatment of ortho- static hypotension with sleeping in the head-up tilt position, alone and in combination with fludrocortisone. J Intern Med 1992;232:139-45.
167. Van Lieshout JJ, Ten Harkel AD, Wieling W. Physical manoeu- vres for combating orthostatic dizziness in autonomic failure. Lancet 1992;339:897-8.
168. Streeten DH, Anderson GH Jr, Richardson R, Thomas FD. Abnormal orthostatic changes in blood pressure and heart rate in subjects with intact sympathetic nervous function: evidence for excessive venous pooling. J Lab Clin Med 1988;111:326-35.
169. Freitas J, Santos R, Azevedo E, Costa O, Carvalho M, de Freitas AF. Clinical improvement in patients with orthostatic intolerance after treatment with bisoprolol and fludrocortisone. Clin Auton Res 2000;10:293-9.
170. Freitas J, Santos R, Azevedo E, Costa O, Carvalho M, de Freitas AF. Reversible sympathetic vasomotor dysfunction in POTS patients. Rev Port Cardiol 2000;19:1163-70.
171. Jacob G, Shannon JR, Black B, et al. Effects of volume loading and pressor agents in idiopathic orthostatic tachycardia. Circulation 1997;96:575-80.
172. Gaffney FA, Lane LB, Pettinger W, Blomqvist CG. Effects of long-term clonidine administration on the hemodynamic and neuroendocrine postural responses of patients with dysautonomia. Chest 1983;83:436-8.
173. Jacob G, Biaggioni I. Idiopathic orthostatic intolerance and pos- tural tachycardia syndromes. Am J Med Sci 1999;317:88-101.
174. Grubb BP, Karas BJ. The potential role of serotonin in the patho- genesis of neurocardiogenic syncope and related autonomic disturbances. J Interv Card Electrophysiol 1998;2:325-32.
175. Hoeldtke RD, Horvath GG, Bryner KD, Hobbs GR. Treatment of orthostatic hypotension with midodrine and octreotide. J Clin Endocrinol Metab 1998;83:339-43.
176. Hoeldtke RD, Horvath GG, Bryner KD. Treatment of orthostatic tachycardia with erythropoietin. Am J Med 1995;99:525-9. 177. Barker P, Wilson F, Johnston D. The mechanism of auricular paroxysmal tachycardia. Am Heart J 1943;26:435-45.
178. Han J, Malozzi A, Moe G. Sino-atrial reciprocationin the isolated rabbit heart. Circulation 1968;22:355-69.
179. Reiffel JA, Bigger JT, Ferrick K, et al. Sinus node echoes and concealed concealed conduction: additional sinus node phenomena confirmed in man by direct sinus node electrography. J Electrocardiol 1985;18:259-66.
180. Ogawa S, Dreifus LS, Osmick MJ. Induction of sinus node reen- try: its relation to inhomogeneous atrial conduction. J Electrocardiol 1978;11:109-16.
181. Narula OS. Sinus node re-entry: a mechanism for supraventricular tachycardia. Circulation 1974;50:1114-28.
182. Griffith MJ, Garratt CJ, Ward DE, Camm AJ. The effects of adenosine on sinus node reentrant tachycardia. Clin Cardiol 1989;12:409-11.
183. Gomes JA, Mehta D, Langan MN. Sinus node reentrant tachycardia. Pacing Clin Electrophysiol 1995;18:1045-57.
184. Kay GN, Chong F, Epstein AE, Dailey SM, Plumb VJ. Radiofrequency ablation for treatment of primary atrial tachycardias. J Am Coll Cardiol 1993;21:901-9.
185. Gomes JA, Hariman RJ, Kang PS, Chowdry IH. Sustained symp- tomatic sinus node reentrant tachycardia: incidence, clinical significance, electrophysiologic observations and the effects of antiarrhythmic agents. J Am Coll Cardiol 1985;5:45-57.
186. Lesh MD, Van Hare GF, Epstein LM, et al. Radiofrequency catheter ablation of atrial arrhythmias. Results and mechanisms. Circulation 1994;89:1074-89.
187. Sanders WE Jr, Sorrentino RA, Greenfield RA, Shenasa H, Hamer ME, Wharton JM. Catheter ablation of sinoatrial node reentrant tachycardia. J Am Coll Cardiol 1994;23:926-34.
188. Goya M, Iesaka Y, Takahashi A, et al. Radiofrequency catheter ablation for sinoatrial node reentrant tachycardia: electrophysiologic features of ablation sites. Jpn Circ J 1999;63:177-83.
189. Akhtar M, Jazayeri MR, Sra J, Blanck Z, Deshpande S, Dhala A. Atrioventricular nodal reentry: clinical, electrophysiological, and therapeutic considerations. Circulation 1993;88:282-95.
190. Sung RJ, Waxman HL, Saksena S, Juma Z. Sequence of retro- grade atrial activation in patients with dual atrioventricular nodal pathways. Circulation 1981;64:1059-67.
191. Sung RJ, Styperek JL, Myerburg RJ, Castellanos A. Initiation of two distinct forms of atrioventricular nodal reentrant tachycardia during programmed ventricular stimulation in man. Am J Cardiol 1978;42:404-15.
192. Winniford MD, Fulton KL, Hillis LD. Long-term therapy of paroxysmal supraventricular tachycardia: a randomized, double- blind comparison of digoxin, propranolol and verapamil. Am J Cardiol 1984;54:1138-9.
193. Rizos I, Seidl KH, Aidonidis I, Stamou S, Senges J, Toutouzas P. Intraindividual comparison of diltiazem and verapamil on induc- tion of paroxysmal supraventricular tachycardia. Cardiology 1994;85:388-96.
194. Anderson JL, Platt ML, Guarnieri T, Fox TL, Maser MJ, Pritchett EL on behalf of the Flecainide Supraventricular Tachycardia Study Group. Flecainide acetate for paroxysmal supraventricular tachyarrhythmias. Am J Cardiol 1994;74:578-84.
195. Neuss H, Schlepper M. Long-term efficacy and safety of fle- cainide for supraventricular tachycardia. Am J Cardiol 1988;62:56D-61D.
196. Musto B, Cavallaro C, Musto A, D’Onofrio A, Belli A, De Vincentis L. Flecainide single oral dose for management of parox- ysmal supraventricular tachycardia in children and young adults. Am Heart J 1992;124:110-5.
197. Pritchett EL, McCarthy EA, Wilkinson WE. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias: a randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med 1991;114:539-44. 198. Tendera M, Wnuk-Wojnar AM, Kulakowski P, et al. Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: a 6-month double-blind comparison with propafenone and placebo. Am Heart J 2001;142: 93-8.
199. Wanless RS, Anderson K, Joy M, Joseph SP. Multicenter com- parative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias. Am Heart J 1997;133:441-6.
200. Wu D, Hung JS, Kuo CT, Hsu KS, Shieh WB. Effects of quini- dine on atrioventricular nodal reentrant paroxysmal tachycardia. Circulation 1981;64:823-31.
201. Wu D, Denes P, Bauernfeind R, Kehoe R, Leon F, Rosen KM. Effects of procainamide on atrioventricular nodal re-entrant paroxysmal tachycardia. Circulation 1978;57:1171-9.
202. Brugada P, Wellens HJ. Effects of intravenous and oral disopyramide on paroxysmal atrioventricular nodal tachycardia. Am J Cardiol 1984;53:88-92.
203. Mauritson DR, Winniford MD, Walker WS, Rude RE, Cary JR, Hillis LD. Oral verapamil for paroxysmal supraventricular tachycardia: a long-term, double-blind randomized trial. Ann Intern Med 1982;96:409-12.
204. Pritchett EL, Hammill SC, Reiter MJ, et al. Life-table methods for evaluating antiarrhythmic drug efficacy in patients with parox- ysmal atrial tachycardia. Am J Cardiol 1983;52:1007-12.
205. Henthorn RW, Waldo AL, Anderson JL, et al, on behalf of the Flecainide Supraventricular Tachycardia Study Group. Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. Circulation 1991;83:119-25.
206. Anderson JL. Long-term safety and efficacy of flecainide in the treatment of supraventricular tachyarrhythmias: the United States experience. The Flecainide Supraventricular Tachyarrhythmia Investigators. Am J Cardiol 1992;70:11A-7A.
207. Dorian P, Naccarelli GV, Coumel P, Hohnloser SH, Maser MJ, for the Flecainide Multicenter Investigators Group. A randomized comparison of flecainide versus verapamil in paroxysmal supraventricular tachycardia. Am J Cardiol 1996;77:89A-95A. 208. UK Propafenone PSVT Study Group. A randomized, placebo- controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. Circulation 1995;92:2550-7.
209. Kopelman HA, Horowitz LN. Efficacy and toxicity of amiodarone for the treatment of supraventricular tachyarrhythmias. Prog Cardiovasc Dis 1989;31:355-66.
210. Gambhir DS, Bhargava M, Nair M, Arora R, Khalilullah M. Comparison of electrophysiologic effects and efficacy of single- dose intravenous and long-term oral amiodarone therapy in patients with AV nodal reentrant tachycardia. Indian Heart J 1996;48:133-7.
211. Alboni P, Tomasi C, Menozzi C, et al. Efficacy and safety of out- of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia. J Am Coll Cardiol 2001;37:548-53.
212. Yeh SJ, Lin FC, Chou YY, Hung JS, Wu D. Termination of paroxysmal supraventricular tachycardia with a single oral dose of diltiazem and propranolol. Circulation 1985;71:104-9.
213. Smith EE, Shore DF, Monro JL, Ross JK. Oral verapamil fails to prevent supraventricular tachycardia following coronary artery surgery. Int J Cardiol 1985;9:37-44.
214. Cox JL, Holman WL, Cain ME. Cryosurgical treatment of atri- oventricular node reentrant tachycardia. Circulation 1987;76:1329-36.
215. Haissaguerre M, Warin JF, Lemetayer P, Saoudi N, Guillem JP, Blanchot P. Closed-chest ablation of retrograde conduction in patients with atrioventricular nodal reentrant tachycardia. N Engl J Med 1989;320:426-33.
216. Epstein LM, Scheinman MM, Langberg JJ, Chilson D, Goldberg HR, Griffin JC. Percutaneous catheter modification of the atri- oventricular node. A potential cure for atrioventricular nodal reentrant tachycardia. Circulation 1989;80:757-68.
217. Hindricks G for the Working Group on Arrhythmias of the European Society of Cardiology. Incidence of complete atrioven- tricular block following attempted radiofrequency catheter modification of the atrioventricular node in 880 patients. Results of the Multicenter European Radiofrequency Survey (MERFS). Eur Heart J 1996;17:82-8.
218. Langberg JJ, Leon A, Borganelli M, et al. A randomized, prospec- tive comparison of anterior and posterior approaches to radiofre- quency catheter ablation of atrioventricular nodal reentry tachy- cardia. Circulation 1993;87:1551-6.
219. Jackman WM, Friday KJ, Fitzgerald DM, Yeung-Lai-Wah JA, Lazzara R. Use of intracardiac recordings to determine the site of drug action in paroxysmal supraventricular tachycardia. Am J Cardiol 1988;62:8L-19L.
220. Kalbfleisch SJ, Strickberger SA, Williamson B, et al. Randomized comparison of anatomic and electrogram mapping approaches to ablation of the slow pathway of atrioventricular node reentrant tachycardia. J Am Coll Cardiol 1994;23:716-23.
221. Otomo K, Wong Z, Lazzara R, et al. Atrioventricular nodal reentrant tachycardia: electrophysiological characteristics of four forms and implications for the reentrant circuit. In: Zipes D, Jalife J, eds. Cardiac electrophysiology: from cell to bedside. Philadelphia, PA: WB Saunders, 2000:504-21.
222. Scheinman MM, Huang S. The 1998 NASPE prospective catheter ablation registry. Pacing Clin Electrophysiol 2000;23:1020-8.
223. Clague JR, Dagres N, Kottkamp H, Breithardt G, Borggrefe M. Targeting the slow pathway for atrioventricular nodal reentrant tachycardia: initial results and long-term follow-up in 379 consecutive patients. Eur Heart J 2001;22:82-8.
224. Lee SH, Chen SA, Tai CT, et al. Atrioventricular node reentrant tachycardia in patients with a prolonged AH interval during sinus rhythm: clinical features, electrophysiologic characteristics and results of radiofrequency ablation. J Interv Card Electrophysiol 1997;1:305-10.
225. Calkins H, Yong P, Miller JM, et al, for the Atakr Multicenter Investigators Group. Catheter ablation of accessory pathways, atrioventricular nodal reentrant tachycardia, and the atrioventricu- lar junction: final results of a prospective, multicenter clinical trial. Circulation 1999;99:262-70.
226. Chen SA, Wu TJ, Chiang CE, et al. Recurrent tachycardia after selective ablation of slow pathway in patients with atrioventricu- lar nodal reentrant tachycardia. Am J Cardiol 1995;76:131-7.
227. Bogun F, Knight B, Weiss R, et al. Slow pathway ablation in patients with documented but noninducible paroxysmal supraven- tricular tachycardia. J Am Coll Cardiol 1996;28:1000-4.
228. Hamdan MH, Dorostkar P, Scheinman M. Junctional tachycardia and junctional rhythm. In: Zipes D, Jalife J, eds. Cardiac Electrophysiology: from cell to bedside. Philadelphia, PA: WB Saunders, 2000:482-8.
229. Kumagai K, Yamato H, Yamanouchi Y, et al. Automatic junction- al tachycardia in an adult. Clin Cardiol 1990;13:813-6.
230. Ruder MA, Davis JC, Eldar M, et al. Clinical and electrophysio- logic characterization of automatic junctional tachycardia in adults. Circulation 1986;73:930-7.
231. Santinelli V, De Paola M, Smimmo D, Turco P, Condorelli M. Junctional ectopic tachycardia in adults. Role of triggered activity. Chest 1987;92:188-9.
232. Kuck KH, Kunze KP, Schluter M, Duckeck W. Encainide versus flecainide for chronic atrial and junctional ectopic tachycardia. Am J Cardiol 1988;62:37L-44L.
233. Cook JR, Steinberg JS. An incessant form of junctional ectopic tachycardia in an adult responsive to a class 1C agent. Am Heart J 1991;122:1487-9.
234. Hamdan M, Van Hare GF, Fisher W, et al. Selective catheter abla- tion of the tachycardia focus in patients with nonreentrant junc- tional tachycardia. Am J Cardiol 1996;78:1292-7.
235. Scheinman MM, Gonzalez RP, Cooper MW, Lesh MD, Lee RJ, Epstein LM. Clinical and electrophysiologic features and role of catheter ablation techniques in adult patients with automatic atrioventricular junctional tachycardia. Am J Cardiol 1994;74:565- 72. 236. Ehlert FA, Goldberger JJ, Deal BJ, Benson DW, Kadish AH. Successful radiofrequency energy ablation of automatic junction- al tachycardia preserving normal atrioventricular nodal conduction. Pacing Clin Electrophysiol 1993;16:54-61.
237. Paul T, Reimer A, Janousek J, Kallfelz HC. Efficacy and safety of propafenone in congenital junctional ectopic tachycardia. J Am Coll Cardiol 1992;20:911-4.
238. Maragnes P, Fournier A, Davignon A. Usefulness of oral sotalol for the treatment of junctional ectopic tachycardia. Int J Cardiol 1992;35:165-7.
239. Villain E, Vetter VL, Garcia JM, Herre J, Cifarelli A, Garson A Jr. Evolving concepts in the management of congenital junctional ectopic tachycardia: a multicenter study. Circulation 1990;81: 1544-9.
240. Fidell J, Do-Ngoc D, Attuel P, et al. L’amiodarone dans le traite- ment des troubles du rythme cardiaque de l’enfant. Arch Mal Coeur Vaiss 1973;2:198-204.
241. Rosen MR, Reder RF. Does triggered activity have a role in the genesis of cardiac arrhythmias? Ann Intern Med 1981;94:794- 801.
242. Storstein O, Hansteen V, Hatle L, Hillestad L, Storstein L. Studies on digitalis. XIII: a prospective study of 649 patients on mainte- nance treatment with digitoxin. Am Heart J 1977;93:434-43.
243. Castellanos A, Sung RJ, Myerburg RJ. His bundle electrocardiography in digitalis-induced “atrioventricular junctional” Wenckebach periods with irregular H-H intervals. Am J Cardiol 1979;43:653-6.
244. Fisch C. Myocardial infarction: accelerated junctional rhythm. J Indiana State Med Assoc 1970;63:350.
245. Breslow MJ, Evers AS, Lebowitz P. Successful treatment of accelerated junctional rhythm with propranolol: possible role of sympathetic stimulation in the genesis of this rhythm disturbance. Anesthesiology 1985;62:180-2.
246. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of electrocardiographic preexcitation in men. The Manitoba Follow-up Study. Ann Intern Med 1992;116:456-60.
247. Sorbo MD, Buja GF, Miorelli M, et al. The prevalence of the Wolff-Parkinson-White syndrome in a population of 116,542 young males. G Ital Cardiol 1995;25:681-7.
248. Vidaillet HJ Jr, Pressley JC, Henke E, Harrell FE Jr, German LD. Familial occurrence of accessory atrioventricular pathways (preexcitation syndrome). N Engl J Med 1987;317:65-9.
249. Murdock CJ, Leitch JW, Teo WS, Sharma AD, Yee R, Klein GJ. Characteristics of accessory pathways exhibiting decremental conduction. Am J Cardiol 1991;67:506-10.
250. Ross DL, Uther JB. Diagnosis of concealed accessory pathways in supraventricular tachycardia. Pacing Clin Electrophysiol 1984;7:1069-85.
251. Klein GJ, Bashore TM, Sellers TD, Pritchett EL, Smith WM, Gallagher JJ. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med 1979;301:1080-5.
252. Dreifus LS, Haiat R, Watanabe Y, Arriaga J, Reitman N. Ventricular fibrillation: a possible mechanism of sudden death in patients and Wolff-Parkinson-White syndrome. Circulation 1971;43:520-7.
253. Munger TM, Packer DL, Hammill SC, et al. A population study of the natural history of Wolff-Parkinson-White syndrome in Olmsted County, Minnesota, 1953-1989. Circulation 1993;87:866-73.
254. Campbell RW, Smith RA, Gallagher JJ, Pritchett EL, Wallace AG. Atrial fibrillation in the preexcitation syndrome. Am J Cardiol 1977;40:514-20.
255. Sharma AD, Klein GJ, Guiraudon GM, Milstein S. Atrial fibrilla- tion in patients with Wolff-Parkinson-White syndrome: incidence after surgical ablation of the accessory pathway. Circulation 1985;72:161-9.
256. Dagres N, Clague JR, Lottkamp H, Hindricks G, Breithardt G, Borggrefe M. Impact of radiofrequency catheter ablation of acces- sory pathways on the frequency of atrial fibrillation during long- term follow-up; high recurrence rate of atrial fibrillation in patients older than 50 years of age. Eur Heart J 2001;22:423-7.
257. Leitch JW, Klein GJ, Yee R, Murdock C. Prognostic value of elec- trophysiology testing in asymptomatic patients with Wolff- Parkinson-White pattern. Circulation 1990;82:1718-23.
258. Timmermans C, Smeets JL, Rodriguez LM, Vrouchos G, van den DA, Wellens HJ. Aborted sudden death in the Wolff-Parkinson- White syndrome. Am J Cardiol 1995;76:492-4.
259. Beckman KJ, Gallastegui JL, Bauman JL, Hariman RJ. The pre- dictive value of electrophysiologic studies in untreated patients with Wolff-Parkinson-White syndrome. J Am Coll Cardiol 1990;15:640-7.
260. Attoyan C, Haissaguerre M, Dartigues JF, Le Metayer P, Warin JF, Clementy J. Ventricular fibrillation in Wolff-Parkinson-White syndrome. Predictive factors. Arch Mal Coeur Vaiss 1994;87:889- 97.
261. Montoya PT, Brugada P, Smeets J, et al. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. Eur Heart J 1991;12:144- 50.
262. Wellens HJ, Bar FW, Gorgels AP, Vanagt EJ. Use of ajmaline in patients with the Wolff-Parkinson-White syndrome to disclose short refractory period of the accessory pathway. Am J Cardiol 1980;45:130-3.
263. Gollob MH, Green MS, Tang AS, et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med 2001;344:1823-31.
264. Klein GJ, Gulamhusein SS. Intermittent preexcitation in the Wolff-Parkinson-White syndrome. Am J Cardiol 1983;52:292-6. 265. Manolis AS, Katsaros C, Cokkinos DV. Electrophysiological and electropharmacological studies in pre- excitation syndromes: results with propafenone therapy and isoproterenol infusion testing. Eur Heart J 1992;13:1489-95.
266. Janousek J, Paul T, Reimer A, Kallfelz HC. Usefulness of propafenone for supraventricular arrhythmias in infants and chil- dren. Am J Cardiol 1993;72:294-300.
267. Musto B, D'Onofrio A, Cavallaro C, Musto A. Electro- physiological effects and clinical efficacy of propafenone in chil- dren with recurrent paroxysmal supraventricular tachycardia. Circulation 1988;78:863-9.
268. Vignati G, Mauri L, Figini A. The use of propafenone in the treat- ment of tachyarrhythmias in children. Eur Heart J 1993;14:546- 50.
269. Vassiliadis I, Papoutsakis P, Kallikazaros I, Stefanadis C. Propafenone in the prevention of non-ventricular arrhythmias associated with the Wolff-Parkinson-White syndrome. Int J Cardiol 1990;27:63-70.
270. Helmy I, Scheinman MM, Herre JM, Sharkey H, Griffin JC. Electrophysiologic effects of isoproterenol in patients with atri- oventricular reentrant tachycardia treated with flecainide. J Am Coll Cardiol 1990;16:1649-55.
271. Kim SS, Lal R, Ruffy R. Treatment of paroxysmal reentrant supraventricular tachycardia with flecainide acetate. Am J Cardiol 1986;58:80-5.
272. Cockrell JL, Scheinman MM, Titus C, et al. Safety and efficacy of oral flecainide therapy in patients with atrioventricular reentrant tachycardia. Ann Intern Med 1991;114:189-94.
273. Hoff PI, Tronstad A, Oie B, Ohm OJ. Electrophysiologic and clin- ical effects of flecainide for recurrent paroxysmal supraventricu- lar tachycardia. Am J Cardiol 1988;62:585-9.
274. Wiseman MN, Elstob JE, Camm AJ, Nathan AW. A study of the use of flecainide acetate in the long-term management of cardiac arrhythmias. Pacing Clin Electrophysiol 1990;13:767-75.
275. Benditt DG, Dunnigan A, Buetikofer J, Milstein S. Flecainide acetate for long-term prevention of paroxysmal supraventricular tachyarrhythmias. Circulation 1991;83:345-9.
276. Pritchett EL, DaTorre SD, Platt ML, McCarville SE, Hougham AJ for the Flecainide Supraventricular Tachycardia Study Group. Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: dose-response stud- ies. J Am Coll Cardiol 1991;17:297-303.
277. Manolis AS, Estes NA, III. Reversal of electrophysiologic effects of flecainide on the accessory pathway by isoproterenol in the Wolff-Parkinson-White syndrome. Am J Cardiol 1989;64:194-8.
278. Kunze KP, Schluter M, Kuck KH. Sotalol in patients with Wolff- Parkinson-White syndrome. Circulation 1987;75:1050-7.
279. Mason JW. Amiodarone. N Engl J Med 1987;316:455-66.
280. Rosenbaum MB, Chiale PA, Ryba D, Elizari MV. Control of tach- yarrhythmias associated with Wolff-Parkinson-White syndrome by amiodarone hydrochloride. Am J Cardiol 1974;34:215-23.
281. Wellens HJ, Lie KI, Bar FW, et al. Effect of amiodarone in the Wolff-Parkinson-White syndrome. Am J Cardiol 1976;38:189-94.
282. Kappenberger LJ, Fromer MA, Steinbrunn W, Shenasa M. Efficacy of amiodarone in the Wolff-Parkinson-White syndrome with rapid ventricular response via accessory pathway during atrial fibrillation. Am J Cardiol 1984;54:330-5.
283. Lai WT, Voon WC, Yen HW, et al. Comparison of the electrophysiologic effects of oral sustained-release and intravenous verapamil in patients with paroxysmal supraventricular tachycardia. Am J Cardiol 1993;71:405-8.
284. Calkins H, Sousa J, el Atassi R, et al. Diagnosis and cure of the Wolff-Parkinson-White syndrome or paroxysmal supraventricular tachycardias during a single electrophysiologic test. N Engl J Med 1991;324:1612-8.
285. Jackman WM, Wang XZ, Friday KJ, et al. Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome) by radiofrequency current. N Engl J Med 1991;324:1605- 11.
286. Kuck KH, Schluter M, Geiger M, Siebels J, Duckeck W. Radiofrequency current catheter ablation of accessory atrioven- tricular pathways. Lancet 1991;337:1557-61.
287. Lesh MD, Van Hare GF, Scheinman MM, Ports TA, Epstein LA. Comparison of the retrograde and transseptal methods for ablation of left free wall accessory pathways. J Am Coll Cardiol 1993;22:542-9.
288. Calkins H, Langberg J, Sousa J, et al. Radiofrequency catheter ablation of accessory atrioventricular connections in 250 patients: abbreviated therapeutic approach to Wolff-Parkinson-White syndrome. Circulation 1992;85:1337-46.
289. Scheinman MM. NASPE Survey on Catheter Ablation. Pacing Clin Electrophysiol 1995;18:1474-8.
290. Hindricks G for the Multicentre European Radiofrequency Survey (MERFS) investigators of the Working Group on Arrhythmias of the European Society of Cardiology. The Multicentre European Radiofrequency Survey (MERFS): compli- cations of radiofrequency catheter ablation of arrhythmias. Eur Heart J 1993;14:1644-53.
291. Brembilla-Perrot B, Ghawi R. Electrophysiological characteris- tics of asymptomatic Wolff-Parkinson-White syndrome. Eur Heart J 1993;14:511-5.
292. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 2001;22:1374-450.
293. Pappone C, Santinelli V, Rosanio S, et al. Usefulness of invasive electrophysiologic testing to stratify the risk of arrhythmic events in asymptomatic patients with Wolff-Parkinson-White pattern: results from a large prospective long-term follow-up study. J Am Coll Cardiol 2003;41:239-44.
294. Saoudi N, Cosio F, Waldo A, et al. A classification of atrial flutter and regular atrial tachycardia according to electrophysiological mechanisms and anatomical bases: a Statement from a Joint Expert Group from the Working Group of Arrhythmias of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 2001;22:1162-82.
295. Steinbeck G, Hoffmann E. 'True' atrial tachycardia. Eur Heart J 1998;19 Suppl E:E10-2, E48-9, E10-9.
296. Simons GR, Wharton JM. Radiofrequency catheter ablation of atrial tachycardia and atrial flutter. Coron Artery Dis 1996;7:12-9.
297. Poutiainen AM, Koistinen MJ, Airaksinen KE, et al. Prevalence and natural course of ectopic atrial tachycardia. Eur Heart J 1999;20:694-700.
298. Garson A Jr, Gillette PC. Electrophysiologic studies of supraven- tricular tachycardia in children. I. Clinical-electrophysiologic cor- relations. Am Heart J 1981;102:233-50.
299. Gillette PC. The mechanisms of supraventricular tachycardia in children. Circulation 1976;54:133-9.
300. Ko JK, Deal BJ, Strasburger JF, Benson DW Jr. Supraventricular tachycardia mechanisms and their age distribution in pediatric patients. Am J Cardiol 1992;69:1028-32.
301. Walsh EP, Saul JP, Hulse JE, et al. Transcatheter ablation of ectopic atrial tachycardia in young patients using radiofrequency current. Circulation 1992;86:1138-46.
302. Wu MH, Lin JL, Lai LP, et al. Radiofrequency catheter ablation of tachycardia in children with and without congenital heart disease: indications and limitations. Int J Cardiol 2000;72:221-7.
303. Wren C. Incessant tachycardias. Eur Heart J 1998;19 Suppl E:E32-6, E54-9..
304. Goldberger J, Kall J, Ehlert F, et al. Effectiveness of radiofrequency catheter ablation for treatment of atrial tachycardia. Am J Cardiol 1993;72:787-93.
305. Tracy CM, Swartz JF, Fletcher RD, et al. Radiofrequency catheter ablation of ectopic atrial tachycardia using paced activation sequence mapping. J Am Coll Cardiol 1993;21:910-7.
306. Chen SA, Chiang CE, Yang CJ, et al. Sustained atrial tachycardia in adult patients: electrophysiological characteristics, pharmaco- logical response, possible mechanisms, and effects of radiofrequency ablation. Circulation 1994;90:1262-78.
307. Poty H, Saoudi N, Haissaguerre M, Daou A, Clementy J, Letac B. Radiofrequency catheter ablation of atrial tachycardias. Am Heart J 1996;131:481-9.
308. Wang L, Weerasooriya HR, Davis MJ. Radiofrequency catheter ablation of atrial tachycardia. Aust N Z J Med 1995;25:127-32.
309. Pappone C, Stabile G, De Simone A, et al. Role of catheter- induced mechanical trauma in localization of target sites of radiofrequency ablation in automatic atrial tachycardia. J Am Coll Cardiol 1996;27:1090-7.
310. Tang CW, Scheinman MM, Van Hare GF, et al. Use of P wave configuration during atrial tachycardia to predict site of origin. J Am Coll Cardiol 1995;26:1315-24.
311. Lee SH, Tai CT, Lin WS, et al. Predicting the arrhythmogenic foci of atrial fibrillation before atrial transseptal procedure: implication for catheter ablation. J Cardiovasc Electrophysiol 2000;11:750-7.
312. SippensGroenewegen A, Peeters HA, Jessurun ER, et al. Body surface mapping during pacing at multiple sites in the human atri- um: P-wave morphology of ectopic right atrial activation. Circulation 1998;97:369-80.
313. Kalman JM, Olgin JE, Karch MR, Hamdan M, Lee RJ, Lesh MD. “Cristal tachycardias”: origin of right atrial tachycardias from the crista terminalis identified by intracardiac echocardiography. J Am Coll Cardiol 1998;31:451-9.
314. Tada H, Nogami A, Naito S, et al. Simple electrocardiographic criteria for identifying the site of origin of focal right atrial tachy- cardia. Pacing Clin Electrophysiol 1998;21:2431-9.
315. Iesaka Y, Takahashi A, Goya M, et al. Adenosine-sensitive atrial reentrant tachycardia originating from the atrioventricular nodal transitional area. J Cardiovasc Electrophysiol 1997;8:854-64.
316. Lai LP, Lin JL, Chen TF, Ko WC, Lien WP. Clinical, electro- physiological characteristics, and radiofrequency catheter abla- tion of atrial tachycardia near the apex of Koch's triangle. Pacing Clin Electrophysiol 1998;21:367-74.
317. Chen SA, Tai CT, Chiang CE, Ding YA, Chang MS. Focal atrial tachycardia: reanalysis of the clinical and electrophysiologic characteristics and prediction of successful radiofrequency ablation. J Cardiovasc Electrophysiol 1998;9:355-65.
318. Chen CC, Tai CT, Chiang CE, et al. Atrial tachycardias originat- ing from the atrial septum: electrophysiologic characteristics and radiofrequency ablation. J Cardiovasc Electrophysiol 2000; 11:744-9.
319. Wagshal AB, Applebaum A, Crystal P, et al. Atrial tachycardia as the presenting sign of a left atrial appendage aneurysm. Pacing Clin Electrophysiol 2000;23:283-5.
320. Mizui S, Mori K, Kuroda Y. Ectopic atrial tachycardia due to aneurysm of the right atrial appendage. Cardiol Young 2001;11:229-32.
321. Nogami A, Suguta M, Tomita T, et al. Novel form of atrial tachy- cardia originating at the atrioventricular annulus. Pacing Clin Electrophysiol 1998;21:2691-4.
322. Chen SA, Hsieh MH, Tai CT, et al. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electro- physiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation 1999;100:1879-86.
323. Tsai CF, Tai CT, Hsieh MH, et al. Initiation of atrial fibrillation by ectopic beats originating from the superior vena cava: electro- physiological characteristics and results of radiofrequency abla- tion. Circulation 2000;102:67-74.
324. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659-66.
325. Ino T, Miyamoto S, Ohno T, Tadera T. Exit block of focal repeti- tive activity in the superior vena cava masquerading as a high right atrial tachycardia. J Cardiovasc Electrophysiol 2000;11:480- 3.
326. Hoffmann E, Reithmann C, Nimmermann P, et al. Clinical expe- rience with electroanatomic mapping of ectopic atrial tachycardia. Pacing Clin Electrophysiol 2002;25:49-56.
327. Wit AL. Cellular electrophysiologic mechanisms of cardiac arrhythmias. Cardiol Clin 1990;8:393-409.
328. Antzelevitch C, Sicouri S. Clinical relevance of cardiac arrhythmias generated by afterdepolarizations: role of M cells in the gen- eration of U waves, triggered activity and torsade de pointes. J Am Coll Cardiol 1994;23:259-77.
329. Goldreyer BN, Gallagher JJ, Damato AN. The electrophysiologic demonstration of atrial ectopic tachycardia in man. Am Heart J 1973;85:205-15.
330. Brugada P, Wellens HJ. The role of triggered activity in clinical ventricular arrhythmias. Pacing Clin Electrophysiol 1984;7:260- 71.
331. Chen SA, Chiang CE, Yang CJ, et al. Radiofrequency catheter ablation of sustained intra-atrial reentrant tachycardia in adult patients: identification of electrophysiological characteristics and endocardial mapping techniques. Circulation 1993;88:578-87.
332. Antman EM, Wenger TL, Butler VP, Jr., Haber E, Smith TW. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments: final report of a multicenter study. Circulation 1990;81:1744-52.
333. Engelstein ED, Lippman N, Stein KM, Lerman BB. Mechanism- specific effects of adenosine on atrial tachycardia. Circulation 1994;89:2645-54.
334. Markowitz SM, Stein KM, Mittal S, Slotwiner DJ, Lerman BB. Differential effects of adenosine on focal and macroreentrant atrial tachycardia. J Cardiovasc Electrophysiol 1999;10:489-502.
335. Lesh MD, Kalman JM, Olgin JE. New approaches to treatment of atrial flutter and tachycardia. J Cardiovasc Electrophysiol 1996;7: 368-81.
336. Coumel P, Leclercq JF, Assayag P. European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias. Am J Cardiol 1984;54:60D-6D.
337. Stock JP. Beta adrenergic blocking drugs in the clinical manage- ment of cardiac arrhythmias. Am J Cardiol 1966;18:444-9. 338. Berns E, Rinkenberger RL, Jeang MK, Dougherty AH, Jenkins M, Naccarelli GV. Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation. Am J Cardiol 1987;59:1337-41.
339. Kunze KP, Kuck KH, Schluter M, Bleifeld W. Effect of encainide and flecainide on chronic ectopic atrial tachycardia. J Am Coll Cardiol 1986;7:1121-6.
340. Beaufort-Krol GC, Bink-Boelkens MT. Sotalol for atrial tachy- cardias after surgery for congenital heart disease. Pacing Clin Electrophysiol 1997;20:2125-9.
341. Prager NA, Cox JL, Lindsay BD, Ferguson TB Jr, Osborn JL, Cain ME. Long-term effectiveness of surgical treatment of ectopic atrial tachycardia. J Am Coll Cardiol 1993;22:85-92.
342. Carrasco HA, Vicuna AV, Molina C, et al. Effect of low oral doses of disopyramide and amiodarone on ventricular and atrial arrhyth- mias of chagasic patients with advanced myocardial damage. Int J Cardiol 1985;9:425-38.
343. Creamer JE, Nathan AW, Camm AJ. Successful treatment of atri- al tachycardias with flecainide acetate. Br Heart J 1985;53:164-6.
344. Pool PE, Quart BD. Treatment of ectopic atrial arrhythmias and premature atrial complexes in adults with encainide. Am J Cardiol 1988;62:60L-2L.
345. Chen SA, Tai CT, Chiang CE, Ding YA, Chang MS. Focal atrial tachycardia: reanalysis of the clinical and electrophysiologic char- acteristics and prediction of successful radiofrequency ablation. J Cardiovasc Electrophysiol 1998;9:355-65.
346. Hsieh MH, Chen SA. Catheter ablation of focal AT. In: Zipes DP, Haissaguerre M, eds. Catheter ablation of arrhythmias. Armonk, NY: Futura Publishing Co., Inc., 2002:185-204.
347. Schmitt C, Zrenner B, Schneider M, et al. Clinical experience with a novel multielectrode basket catheter in right atrial tachy- cardias. Circulation 1999;99:2414-22.
348. Natale A, Breeding L, Tomassoni G, et al. Ablation of right and left ectopic atrial tachycardias using a three- dimensional nonfluoroscopic mapping system. Am J Cardiol 1998;82:989-92.
349. Weiss C, Willems S, Cappato R, Kuck KH, Meinertz T. High fre- quency current ablation of ectopic atrial tachycardia. Different mapping strategies for localization of right- and left-sided origin. Herz 1998;23:269-79.
350. Anguera I, Brugada J, Roba M, et al. Outcomes after radiofrequency catheter ablation of atrial tachycardia. Am J Cardiol 2001;87:886-90.
351. Harrison DA, Siu SC, Hussain F, MacLoghlin CJ, Webb GD, Harris L. Sustained atrial arrhythmias in adults late after repair of tetralogy of fallot. Am J Cardiol 2001;87:584-8.
352. Shine KI, Kastor JA, Yurchak PM. Multifocal atrial tachycardia. Clinical and electrocardiographic features in 32 patients. N Engl J Med 1968;279:344-9.
353. Salerno DM, Anderson B, Sharkey PJ, Iber C. Intravenous vera- pamil for treatment of multifocal atrial tachycardia with and without calcium pretreatment. Ann Intern Med 1987;107:623-8.
354. Arsura E, Lefkin AS, Scher DL, Solar M, Tessler S. A random- ized, double-blind, placebo-controlled study of verapamil and metoprolol in treatment of multifocal atrial tachycardia. Am J Med 1988;85:519-24.
355. Wang K, Goldfarb BL, Gobel FL, Richman HG. Multifocal atrial tachycardia. Arch Intern Med 1977;137:161-4.
356. Saoudi N, Nair M, Abdelazziz A, et al. Electrocardiographic patterns and results of radiofrequency catheter ablation of clockwise type I atrial flutter. J Cardiovasc Electrophysiol 1996;7:931-42.
357. Kalman JM, Olgin JE, Saxon LA, Lee RJ, Scheinman MM, Lesh MD. Electrocardiographic and electrophysiologic characteriza- tion of atypical atrial flutter in man: use of activation and entrainment mapping and implications for catheter ablation. J Cardiovasc Electrophysiol 1997;8:121-44.
358. Cosio FG, Arribas F, Lopez-Gil M, Gonzalez HD. Atrial flutter mapping and ablation II. Radiofrequency ablation of atrial flutter circuits. Pacing Clin Electrophysiol 1996;19:965-75.
359. Cheng J, Scheinman MM. Acceleration of typical atrial flutter due to double-wave reentry induced by programmed electrical stimulation. Circulation 1998;97:1589-96.
360. Cheng J, Cabeen WR Jr, Scheinman MM. Right atrial flutter due to lower loop reentry: mechanism and anatomic substrates. Circulation 1999;99:1700-5.
361. Yang Y, Cheng J, Bochoeyer A, et al. Atypical right atrial flutter patterns. Circulation 2001;103:3092-8.
362. Friedman PA, Luria D, Fenton AM, et al. Global right atrial mapping of human atrial flutter: the presence of posteromedial (sinus venosa region) functional block and double potentials: a study in biplane fluoroscopy and intracardiac echocardiography. Circulation 2000;101:1568-77.
363. Olgin JE, Kalman JM, Fitzpatrick AP, Lesh MD. Role of right atrial endocardial structures as barriers to conduction during human type I atrial flutter: activation and entrainment mapping guided by intracardiac echocardiography. Circulation 1995;92:1839-48.
364. Waldo AL. Pathogenesis of atrial flutter. J Cardiovasc Electro- physiol 1998;9:S18-25.
365. Boyden PA, Graziano JN. Activation mapping of reentry around an anatomical barrier in the canine atrium: observations during the action of the class III agent, d-sotalol. J Cardiovasc Electro- physiol 1993;4:266-79.
366. Waldo AL, MacLean WA, Karp RB, Kouchoukos NT, James TN. Entrainment and interruption of atrial flutter with atrial pacing: studies in man following open heart surgery. Circulation 1977;56:737-45.
367. Saxon LA, Kalman JM, Olgin JE, Scheinman MM, Lee RJ, Lesh MD. Results of radiofrequency catheter ablation for atrial flutter. Am J Cardiol 1996;77:1014-6.
368. Sung RJ, Castellanos A, Mallon SM, Bloom MG, Gelband H, Myerburg RJ. Mechanisms of spontaneous alternation between reciprocating tachycardia and atrial flutter-fibrillation in the Wolff-Parkinson-White syndrome. Circulation 1977;56:409-16.
369. Gelatt M, Hamilton RM, McCrindle BW, et al. Arrhythmia and mortality after the Mustard procedure: a 30-year single- center experience. J Am Coll Cardiol 1997;29:194-201.
370. Gewillig M, Wyse RK, de Leval MR, Deanfield JE. Early and late arrhythmias after the Fontan operation: predisposing factors and clinical consequences. Br Heart J 1992;67:72-9.
371. Li W, Somerville J. Atrial flutter in grown-up congenital heart (GUCH) patients. Clinical characteristics of affected population. Int J Cardiol 2000;75:129-37.
372. Puley G, Siu S, Connelly M, et al. Arrhythmia and survival in patients >18 years of age after the mustard procedure for complete transposition of the great arteries. Am J Cardiol 1999;83:1080-4.
373. Rhodes LA, Wernovsky G, Keane JF, et al. Arrhythmias and intracardiac conduction after the arterial switch operation. J Thorac Cardiovasc Surg 1995;109:303-10.
374. Roos-Hesselink J, Perlroth MG, McGhie J, Spitaels S. Atrial arrhythmias in adults after repair of tetralogy of Fallot. Correlations with clinical, exercise, and echocardiographic find- ings. Circulation 1995;91:2214-9.
375. Heinz G, Siostrzonek P, Kreiner G, Gossinger H. Improvement in left ventricular systolic function after successful radiofrequency His bundle ablation for drug refractory, chronic atrial fibrillation and recurrent atrial flutter. Am J Cardiol 1992;69:489-92.
376. Ellenbogen KA, Dias VC, Plumb VJ, Heywood JT, Mirvis DM. A placebo-controlled trial of continuous intravenous diltiazem infu- sion for 24-hour heart rate control during atrial fibrillation and atrial flutter: a multicenter study. J Am Coll Cardiol 1991;18:891- 7.
377. Goldenberg IF, Lewis WR, Dias VC, Heywood JT, Pedersen WR. Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure. Am J Cardiol 1994;74:884-9.
378. Schreck DM, Rivera AR, Tricarico VJ. Emergency management of atrial fibrillation and flutter: intravenous diltiazem versus intra- venous digoxin. Ann Emerg Med 1997;29:135-40.
379. Platia EV, Michelson EL, Porterfield JK, Das G. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol 1989;63:925-9.
380. Phillips BG, Gandhi AJ, Sanoski CA, Just VL, Bauman JL. Comparison of intravenous diltiazem and verapamil for the acute treatment of atrial fibrillation and atrial flutter. Pharmacotherapy 1997;17:1238-45.
381. Chew CY, Hecht HS, Collett JT, McAllister RG, Singh BN. Influence of severity of ventricular dysfunction on hemodynamic responses to intravenously administered verapamil in ischemic heart disease. Am J Cardiol 1981;47:917-22.
382. Hou ZY, Chang MS, Chen CY, et al. Acute treatment of recent- onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone: a randomized, digoxin-controlled study. Eur Heart J 1995;16:521-8.
383. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT for the Ibutilide Repeat Dose Study Investigators. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996;94:1613-21.
384. Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intra- venous ibutilide for rapid termination of atrial fibrillation and atri- al flutter: a dose-response study. J Am Coll Cardiol 1996;28:130- 6.
385. Volgman AS, Carberry PA, Stambler B, et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol 1998;31:1414-9.
386. Stambler BS, Wood MA, Ellenbogen KA. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determi- nants of enhanced conversion efficacy. Circulation 1997;96:4298- 306.
387. Suttorp MJ, Kingma JH, Jessurun ER, Lie AH, van Hemel NM, Lie KI. The value of class IC antiarrhythmic drugs for acute con- version of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 1990;16:1722-7.
388. Kingma JH, Suttorp MJ. Acute pharmacologic conversion of atri- al fibrillation and flutter: the role of flecainide, propafenone, and verapamil. Am J Cardiol 1992;70:56A-60A.
389. Sung RJ, Tan HL, Karagounis L, et al. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-con- trolled study. Sotalol Multicenter Study Group. Am Heart J ?1995;129:739-48.
390. Vos MA, Golitsyn SR, Stangl K, et al, for the Ibutilide/Sotalol Comparator Study Group. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibril- lation. Heart 1998;79:568-75.
391. Lown B. Electrical reversion of cardiac arrhythmias. Br Heart J 1967;29:469-89.
392. Zeft HJ, Cobb FR, Waxman MB, Hunt NC, Morris JJ Jr. Right atrial stimulation in the treatment of atrial flutter. Ann Intern Med 1969;70:447-56.
393. Gulotta SJ, Aronson AL. Cardioversion of atrial tachycardia and flutter by atrial stimulation. Am J Cardiol 1970;26:262-9. 394. Pittman DE, Makar JS, Kooros KS, Joyner CR. Rapid atrial stim- ulation: successful method of conversion of atrial flutter and atri- al tachycardia. Am J Cardiol 1973;32:700-6.
395. Das G, Anand KM, Ankineedu K, Chinnavaso T, Talmers FN, Weissler AM. Atrial pacing for cardioversion of atrial flutter in digitalized patients. Am J Cardiol 1978;41:308-12.
396. Doni F, Manfredi M, Piemonti C, et al. New onset atrial flutter termination by overdrive transoesophageal pacing: effects of dif- ferent protocols of stimulation. Europace 2000;2:292-6.
397. Tucker KJ, Wilson C. A comparison of transoesophageal atrial pacing and direct current cardioversion for the termination of atrial flutter: a prospective, randomised clinical trial. Br Heart J 1993;69:530-5.
398. Rostas L, Antal K, Putorek Z. Transesophageal pacemaker thera- py in atrial flutter after procainamide pretreatment. Am J Ther 1999;6:237-40.
399. Doni F, Della BP, Kheir A, et al. Atrial flutter termination by overdrive transesophageal pacing and the facilitating effect of oral propafenone. Am J Cardiol 1995;76:1243-6.
400. Doni F, Staffiere E, Manfredi M, et al. Type II atrial flutter inter- ruption with transesophageal pacing: use of propafenone and possible change of the substrate. Pacing Clin Electrophysiol 1996;19:1958-61.
401. Stambler BS, Wood MA, Ellenbogen KA. Comparative efficacy of intravenous ibutilide versus procainamide for enhancing termination of atrial flutter by atrial overdrive pacing. Am J Cardiol 1996;77:960-6.
402. D'Este D, Bertaglia E, Mantovan R, Zanocco A, Franceschi M, Pascotto P. Efficacy of intravenous propafenone in termination of atrial flutter by overdrive transesophageal pacing previously inef- fective. Am J Cardiol 1997;79:500-2.
403. Giorgberidze I, Saksena S, Mongeon L, et al. Effects of high-fre- quency atrial pacing in atypical atrial flutter and atrial fibrillation. J Interv Card Electrophysiol 1997;1:111-23.
404. Hii JT, Mitchell LB, Duff HJ, Wyse DG, Gillis AM. Comparison of atrial overdrive pacing with and without extrastimuli for termination of atrial flutter. Am J Cardiol 1992;70:463-7.
405. Naccarelli GV, Dorian P, Hohnloser SH, Coumel P for the Flecainide Multicenter Atrial Fibrillation Study Group. Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. Am J Cardiol 1996;77:53A-9A. 406. Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symp- tomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000;102:2385-90.
407. Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp- Pedersen C. Efficacy of dofetilide in the treatment of atrial fibril- lation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 2001;104:292-6.
408. Benditt DG, Williams JH, Jin J, et al, for the d,l-Sotalol Atrial Fibrillation/Flutter Study Group. Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. Am J Cardiol 1999;84:270-7.
409. Arnold AZ, Mick MJ, Mazurek RP, Loop FD, Trohman RG. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol 1992;19:851-5.
410. Mancini GB, Goldberger AL. Cardioversion of atrial fibrillation: consideration of embolization, anticoagulation, prophylactic pacemaker, and long-term success. Am Heart J 1982;104:617-21.
411. Dunn M, Alexander J, de Silva R, Hildner F. Antithrombotic therapy in atrial fibrillation. Chest 1989;95:118S-27S.
412. Dunn MI. Thrombolism with atrial flutter. Am J Cardiol 1998;82:638.
413. Seidl K, Hauer B, Schwick NG, Zellner D, Zahn R, Senges J. Risk of thromboembolic events in patients with atrial flutter. Am J Cardiol 1998;82:580-3.
414. Lanzarotti CJ, Olshansky B. Thromboembolism in chronic atrial flutter: is the risk underestimated? J Am Coll Cardiol 1997;30:1506-11.
415. Wood KA, Eisenberg SJ, Kalman JM, et al. Risk of thromboem- bolism in chronic atrial flutter. Am J Cardiol 1997;79:1043-7.
416. Irani WN, Grayburn PA, Afridi I. Prevalence of thrombus, spon- taneous echo contrast, and atrial stunning in patients undergoing cardioversion of atrial flutter: a prospective study using trans- esophageal echocardiography. Circulation 1997;95:962-6. 417. Weiss R, Marcovitz P, Knight BP, et al. Acute changes in sponta- neous echo contrast and atrial function after cardioversion of persistent atrial flutter. Am J Cardiol 1998;82:1052-5.
418. Bikkina M, Alpert MA, Mulekar M, Shakoor A, Massey CV, Covin FA. Prevalence of intraatrial thrombus in patients with atri- al flutter. Am J Cardiol 1995;76:186-9.
419. Grimm RA, Stewart WJ, Arheart K, Thomas JD, Klein AL. Left atrial appendage “stunning” after electrical cardioversion of atrial flutter: an attenuated response compared with atrial fibrillation as the mechanism for lower susceptibility to thromboembolic events. J Am Coll Cardiol 1997;29:582-9.
420. Sparks PB, Jayaprakash S, Vohra JK, et al. Left atrial “stunning” following radiofrequency catheter ablation of chronic atrial flutter. J Am Coll Cardiol 1998;32:468-75.
421. Lip GY, Kamath S. Thromboprophylaxis for atrial flutter. Eur Heart J 2001;22:984-7.
422. Cosio FG, Goicolea A, Lopez-Gil M, Arribas F. Catheter ablation of atrial flutter circuits. Pacing Clin Electrophysiol 1993;16:637- 42.